top of page
  • Recruiting

NCT04483206: Phase 1: Personalized Autologous Transplant for Multiple Myeloma

Updated: Jan 27

  • NCT04483206: Phase 1: Personalized Autologous Transplant for Multiple Myeloma


personalized transplant


Personalized Autologous Transplant for Multiple Myeloma


This phase I trial studies the best dose and side effects of mephalan in treating patients with multiple myeloma who are undergoing stem cell transplant. Chemotherapy drugs, such as mephalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial uses a new method of dosing that is based on analysis of each individual's blood levels of melphalan after receiving a part of the dose, termed pharmacokinetic analysis. This may help to learn more about how to dose melphalan correctly and which patients are likely to benefit from a personalized dose.


Sponsor:

Emory University


Collaborators:

National Cancer Institute (NCI)

Gateway for Cancer Research


Location

United States, Georgia

 

ClinicalTrials.gov Identifier: NCT04483206


Official Title: Phase 1 of Exposure Targeted Melphalan Dosing

First Posted: July 23, 2020

Click here for details on ClinicalTrials.gov

 

Procedure: Autologous Hematopoietic Stem Cell Transplantation

Drug: Melphalan

Other: Questionnaire Administration

 

Locations

United States, Georgia

United States, Illinois










Comments


Commenting has been turned off.
Posts Archive
bottom of page